=== PAGE 7 ===

COMPLETE PAGE ANALYSIS:
--------------------------------------------------
Here is the extracted text content from the PDF page, preserving its original layout and structure:

Chris Jewell
Taiho Oncology, Inc.
NDA 214801/MA 89

Additionally, the response submission should be coded as an Amendment to eCTD
Sequence 5046 under NDA 214801. Questions related to the submission of your response
letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Rebecca Falter, PharmD, BCACP
Regulatory Review Officer
Division of Advertising & Promotion Review 1
Office of Prescription Drug Promotion

{See appended electronic signature page}

Emily Dvorsky, PharmD, RAC
Team Leader
Division of Advertising & Promotion Review 1
Office of Prescription Drug Promotion

Reference ID: 5554583

Page 7
